Recombinant Human TRANCE/RANK L/TNFSF11 Protein
Catalog # 390-TN | R&D Systems, Inc. a Bio-Techne Brand
Key Product Details
Source: | NS0 |
Accession #: | AAC51762 |
Applications: | Bioactivity |
Customers also Viewed
Citations for Recombinant Human TRANCE/RANK L/TNFSF11 Protein (39)
Citations are publications that use Bio-Techne products. Selected citations for Recombinant Human TRANCE/RANK L/TNFSF11 Protein include:
-
Species: Human
Sample Types: Whole Cells
Applications: Cell CultureJ Pape et al. (2022-12-24), RANKL neutralisation prevents osteoclast activation in a human in vitro ameloblastoma-bone model Journal of tissue engineering, 2022-113(0):2041731422114.
PMID: 36582941 -
Species: Rat
Sample Types: Whole Cells
Applications: BioassayD Ding et al. (2022-07-28), Zoledronic acid generates a spatiotemporal effect to attenuate osteoarthritis by inhibiting potential Wnt5a-associated abnormal subchondral bone resorption PLoS ONE, 2022-017(7):e0271485.
PMID: 35900969 -
Species: Mouse
Sample Types: Whole Cells
Applications: BioassayH Guo et al. (2021-12-16), Metformin attenuates osteoclast-mediated abnormal subchondral bone remodeling and alleviates osteoarthritis via AMPK/NF-kappaB/ERK signaling pathway PLoS ONE, 2021-116(12):e0261127.
PMID: 34914744 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayJ Xue et al. (2020-09-21), CD14+CD16- monocytes are the main precursors of osteoclasts in rheumatoid arthritis via expressing Tyro3TK Arthritis Research Therapy, 2020-09-21;22(1):221.
PMID: 32958023 -
Species: Human
Sample Types: Whole Cells
Applications: Cell CultureJS Brunner et al. (2020-01-22), Environmental arginine controls multinuclear giant cell metabolism and formation Nat Commun, 2020-011(1):431.
PMID: 31969567 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayKA Lee et al. (2019-12-12), Promotion of osteoclastogenesis by IL-26 in rheumatoid arthritis Arthritis Res. Ther., 2019-121(1):283.
PMID: 31831038 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayI Zoi et al. (2019-12-03), Combining RANK/RANKL and ERBB-2 targeting as a novel strategy in ERBB-2-positive breast carcinomas Breast Cancer Res., 2019-121(1):132.
PMID: 31796128 -
Species: Human
Sample Types: Whole Cells
Applications: Cell CultureK Li et al. (2019-11-06), MiRNA-483-5p is involved in the pathogenesis of osteoporosis by promoting osteoclast differentiation Mol. Cell. Probes, 2019-10(0):101479.
PMID: 31706013 -
Species: Human
Sample Types: Whole Cells
Applications: Cell CultureN Ogasawara et al. (2019-10-22), Role of RANK-L as a potential inducer of ILC2-mediated type 2 inflammation in chronic rhinosinusitis with nasal polyps Mucosal Immunol, 2019-113(1):86-95.
PMID: 31641233 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayIJ Yeh et al. (2019-09-28), 6-Shogaol Suppresses 2-Amino-1-Methyl-6-Phenylimidazo [4,5-b] Pyridine (PhIP)-Induced Human 786-O Renal Cell Carcinoma Osteoclastogenic Activity and Metastatic Potential Nutrients, 2019-011(10).
PMID: 31569368 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayFL Collins et al. (2019-07-12), Oestrogen-deficiency induces bone loss by modulating CD14+ monocyte and CD4+ T cell DR3 expression and serum TL1A levels BMC Musculoskelet Disord, 2019-020(1):326.
PMID: 31299941 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayH Löfvall et al. (2019-02-28), GPDPLQ1237-A Type II Collagen Neo-Epitope Biomarker of Osteoclast- and Inflammation-Derived Cartilage Degradation in vitro Sci Rep, 2019-09(1):3050.
PMID: 30816326 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayAMJ Møller et al. (2018-08-29), Septins are critical regulators of osteoclastic bone resorption Sci Rep, 2018-08(1):13016.
PMID: 30158637 -
Species: Human
Sample Types: Whole Cells
Applications: Cell CultureCF Kjelgaard- et al. (2018-07-24), Translational Biomarkers and Ex Vivo Models of Joint Tissues as a Tool for Drug Development in Rheumatoid Arthritis Arthritis rheumatology (Hoboken, N.J.), 2018-07-24;0(0).
PMID: 29669391 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayC Davenport et al. (2018-04-10), RANKL Inhibits the Production of Osteoprotegerin from Smooth Muscle Cells under Basal Conditions and following Exposure to Cyclic Strain J. Vasc. Res., 2018-055(2):111-123.
PMID: 29635231 -
Species: Human
Sample Types: Recombinant Protein
Applications: Surface Plasmon Resonance (SPRAW Clarke et al. (2018-03-05), An anti-TL1A antibody for the treatment of asthma and inflammatory bowel disease MAbs, 2018-00(0):1-43.
PMID: 29436901 -
Species: Equine
Sample Types: Whole Cells
Applications: BioassayH Hussein et al. (2017-12-18), Cathepsin K Localizes to Equine Boneand Inhibits Bone Marrow Stem and Progenitor Cells Differentiation J Stem Cells Regen Med, 2017-113(2):45-53.
PMID: 29391749 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayA Sucur et al. (2017-06-15), Chemokine signals are crucial for enhanced homing and differentiation of circulating osteoclast progenitor cells Arthritis Res. Ther., 2017-019(1):142.
PMID: 28619088 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayB Lu et al. (2017-05-19), A FKBP5 mutation is associated with Paget's disease of bone and enhances osteoclastogenesis Exp. Mol. Med., 2017-049(5):e336.
PMID: 28524179 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayG Chinetti-G et al. (2017-04-24), Human Alternative Macrophages Populate Calcified Areas of Atherosclerotic Lesions and Display Impaired RANKL-Induced Osteoclastic Bone Resorption Activity Circ. Res., 2017-00(0).
PMID: 28438779 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayA Kamalakar et al. (2017-04-19), PTHrP(12-48) Modulates the Bone Marrow Microenvironment and Suppresses Human Osteoclast Differentiation and Lifespan J. Bone Miner. Res., 2017-00(0).
PMID: 28370412 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayGiulia Bellini (2016-12-02), PKC?II-mediated cross-talk of TRPV1/CB2 modulates the glucocorticoid-induced osteoclast overactivity Pharmacol. Res, 2016-10(0).
PMID: 27919827 -
Sample Types: Protein
Applications: BioassayJustin R Savage (2016-06-16), A Modified Glycosaminoglycan, GM-0111, Inhibits Molecular Signaling Involved in Periodontitis PLoS ONE, 2016-011(6):e0157310.
PMID: 27308827 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayKasonga A et al. (2015-04-13), Arachidonic acid and docosahexaenoic acid suppress osteoclast formation and activity in human CD14+ monocytes, in vitro. PLoS ONE, 2015-010(4):e0125145.
PMID: 25867515 -
Species: Mouse
Sample Types: Whole Cells
Applications: BioassayZhu K et al. (2015-02-03), Impaired bone homeostasis in amyotrophic lateral sclerosis mice with muscle atrophy. J Biol Chem, 2015-0290(13):8081-94.
PMID: 25648889 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayKalbasi Anaraki P et al. (2015-02-01), Urokinase receptor mediates osteoclastogenesis via M-CSF release from osteoblasts and the c-Fms/PI3K/Akt/NF-kappaB pathway in osteoclasts. J Bone Miner Res, 2015-030(2):379-88.
PMID: 25196912 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayAlshbool F et al. (2014-12-05), Differential expression of claudin family members during osteoblast and osteoclast differentiation: Cldn-1 is a novel positive regulator of osteoblastogenesis. PLoS ONE, 2014-19(12):e114357.
PMID: 25479235 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayZheng Y et al. (2014-09-01), Direct crosstalk between cancer and osteoblast lineage cells fuels metastatic growth in bone via auto-amplification of IL-6 and RANKL signaling pathways. J Bone Miner Res, 2014-029(9):1938-49.
PMID: 24676805 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayYeon J et al. (2014-02-21), Anti-osteoclastogenic activity of praeruptorin A via inhibition of p38/Akt-c-Fos-NFATc1 signaling and PLCgamma-independent Ca2+ oscillation. PLoS ONE, 2014-09(2):e88974.
PMID: 24586466 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayChen C et al. (2014-02-01), MiR-503 regulates osteoclastogenesis via targeting RANK. J Bone Miner Res, 2014-029(2):338-47.
PMID: 23821519 -
Species: Human
Applications: BioassayLiu Z et al. (2013-12-10), Bone marrow stromal cells derived MCP-1 reverses the inhibitory effects of multiple myeloma cells on osteoclastogenesis by upregulating the RANK expression. PLoS ONE, 2013-18(12):e82453.
PMID: 24340030 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayHe W et al. (2013-05-16), Adenosine regulates bone metabolism via A1, A2A, and A2B receptors in bone marrow cells from normal humans and patients with multiple myeloma. FASEB J, 2013-027(9):3446-54.
PMID: 23682121 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayWilson TR et al. (2012-07-26), Widespread potential for growth-factor-driven resistance to anticancer kinase inhibitors. Nature, 2012-0487(7408):505-9.
PMID: 22763448 -
Species: Human
Sample Types: Whole Cells
Applications: BioassaySoe K et al. (2010-10-01), Glucocorticoids maintain human osteoclasts in the active mode of their resorption cycle. J. Bone Miner. Res., 2010-125(10):2184-92.
PMID: 20499345 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayBoissy P et al. (2008-04-18), Pulse treatment with the proteasome inhibitor bortezomib inhibits osteoclast resorptive activity in clinically relevant conditions. Leuk. Res., 2008-032(11):1661-8.
PMID: 18394701 -
Species: Human
Sample Types: Whole Cells
Applications: BioassayColucci S et al. (2007-05-01), Lymphocytes and synovial fluid fibroblasts support osteoclastogenesis through RANKL, TNFalpha, and IL-7 in an in vitro model derived from human psoriatic arthritis. J. Pathol., 2007-0212(1):47-55.
PMID: 17370327 -
Species: Mouse
Sample Types: Whole Cells
Applications: BioassayTang CH et al. (2006-11-10), Attenuation of bone mass and increase of osteoclast formation in decoy receptor 3 transgenic mice. J. Biol. Chem., 2006-1282(4):2346-54.
PMID: 17099218 -
Species: Mouse
Sample Types: Whole Cells
Applications: BioassayKawai T et al. (2006-09-01), B and T lymphocytes are the primary sources of RANKL in the bone resorptive lesion of periodontal disease. Am. J. Pathol., 2006-0169(3):987-98.
PMID: 16936272 -
Sample Types: N/A
Applications: ELISA (Standard)Grimaud E et al. (2003-11-01), Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. Am. J. Pathol., 2003-1163(5):2021-31.
PMID: 14578201
There are no citations that match your criteria.
Customer Reviews for Recombinant Human TRANCE/RANK L/TNFSF11 Protein (8)
Customer Images
-
Application: In vitro bioactivity in cell cultureVerified Customer | Posted 05/17/2022
-
Application: In vitro bioactivity in cell cultureReason for Rating: Steady quality! 60 ng/ml RANKL can induce monocyte to osteoclast very well.Verified Customer | Posted 12/31/2021
-
Application: In vitro bioactivity in cell cultureReason for Rating: 50ng/ml RANKL is good for induce the human monocyte to osteoclast.Verified Customer | Posted 03/20/2021
-
Application: In vitro bioactivity in cell cultureReason for Rating: 50ng/ml RANKL, 25ng/ml M-CSF in a-MEM works well for human osteoclasts.Verified Customer | Posted 01/18/2021
-
Application: CellProlifVerified Customer | Posted 02/06/2019
-
Application: Characterization by MSVerified Customer | Posted 01/05/2018
-
Verified Customer | Posted 05/16/2017
-
Application: CellProlifVerified Customer | Posted 05/18/2016
There are no reviews that match your criteria.
FAQs for Recombinant Human TRANCE/RANK L/TNFSF11 Protein
-
This protein datasheet indicates I need to use a cross-linking antibody, Catalog # MAB050, for biological activity. What is this antibody and is it really necessary?
The antibody is directed against a 6x histidine repeat and is recommended for use as a cross-linker of proteins with 6x his-tag. Crosslinking is often used for proteins that require receptor trimerization and can result greater biological activity. R&D Systems Quality Control tests the performance of these proteins in the presence of the cross-linking antibody. Therefore, it is necessary to use this antibody when trying to achieve the same level of specific activity described in the datasheet.
-
Is this protein provided in trimeric form or monomer form?
We do not define this protein as being exclusively a monomer, but we know that the protein is not fully associated into trimers because we need to use a cross-linking antibody for our in-house activity testing to cause multiple subunits of this protein to associate. This product has been shown to be biologically active in such testing when a cross-linking antibody is used. Therefore, we would expect for this protein to perform its expected biological function.
-
What are the differences between the Recombinant Human TRANCE/RANK L/TNFSF11 Protein (Catalog # 390-TN) and the Recombinant Human TRANCE/RANK L/TNFSF11 (Catalog # 6449-TEC)?
6449-TEC is the truncated version of 390-TN, and it contains a 10-His tag in the N-terminus. The bioactivity of 390-TN and 6449-TEC are measured in the same assay described in the datasheet, "Measured by its ability to induce osteoclast differentiation of RAW 264.7 mouse monocyte/macrophage cells." However, 390-TN utilizes a cross-linking antibody, MAB050, as it requires receptor trimerization which results in higher bioactivity. The ED50 for 390-TN is 1.5-7.5 ng/mL in the presence of MAB050, while the ED50 for 6449-TEC is 2-12 ng/mL.